• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Chem . Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity

tetano

Editor, Senior Moderator
J Med Chem


. 2025 Aug 7.
doi: 10.1021/acs.jmedchem.5c00581. Online ahead of print. Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 M[SUP]pro[/SUP] Inhibitor with Pan-Coronavirus Activity

Qian Wen Tan[SUP] 1 [/SUP], Subramanyam Vankadara[SUP] 1 [/SUP], Jia Yi Fong[SUP] 1 [/SUP], Yi Yang See[SUP] 1 [/SUP], Nithya Baburajendran[SUP] 1 [/SUP], Pearly Shuyi Ng[SUP] 1 [/SUP], Weijun Xu[SUP] 1 [/SUP], Yee Khoon Yeo[SUP] 1 [/SUP], Weiling Wang[SUP] 1 [/SUP], Choon Heng Low[SUP] 1 [/SUP], Li Hong Tan[SUP] 1 [/SUP], Eileen Gui Ju Tay[SUP] 1 [/SUP], Yun Xuan Wong[SUP] 1 [/SUP], Chuhui Huang[SUP] 1 [/SUP], Sandra Sim[SUP] 1 [/SUP], Shi Hua Ang[SUP] 1 [/SUP], Hannah Hui Min Toh[SUP] 1 [/SUP], Juliana Mohammad[SUP] 1 [/SUP], Gang Wang[SUP] 1 [/SUP], Boping Liu[SUP] 1 [/SUP], Shu Ting Tan[SUP] 1 [/SUP], Perlyn Zekui Kwek[SUP] 1 [/SUP], Monique Danielle Dawson[SUP] 1 [/SUP], Qin Yao Oh[SUP] 1 [/SUP], Xiaoying Koh[SUP] 1 [/SUP], Joma Joy[SUP] 1 [/SUP], May Ann Lee[SUP] 1 [/SUP], Walter Stunkel[SUP] 1 [/SUP], Vishal Pendharkar[SUP] 1 [/SUP], Hannes Hentze[SUP] 1 [/SUP], Siew Pheng Lim[SUP] 1 [/SUP], Kantharaj Ethirajulu[SUP] 1 [/SUP], C S Brian Chia[SUP] 1 [/SUP], Joseph Cherian[SUP] 1 [/SUP]



Affiliations
Abstract

Resulting in several million deaths globally, the COVID-19 pandemic has highlighted the criticality of antiviral drugs during a viral pandemic. Herein, we describe our efforts toward targeting SARS-CoV-2 M[SUP]pro[/SUP], a key viral protease, which led to the discovery of compound 18, a reversible covalent inhibitor with potent antiviral activity against several clinical variants of SARS-CoV-2. Compound 18 demonstrated dose-dependent efficacy in a mouse-adapted SARS-CoV-2 infection model, with favorable pharmacokinetic profiles in mice, rats, dogs, and monkeys.


 
Back
Top Bottom